Everolimus: all 667 studies that test it
Page 5 of 7. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone AcetateCompletedNCT02106507Phase 1
- MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney TransplantationStatus unknownNCT02091973Not applicable
- Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal TransplantCompletedNCT02084446Phase 4
- Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1
- Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant PatientsCompletedNCT02077556Phase 4
- Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant PatientsWithdrawnNCT02062892Phase 4
- Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab TreatmentCompletedNCT02056587Phase 4
- Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With ChemotherapyCompletedNCT02049047Phase 2
- Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft RecipientsStatus unknownNCT02036554Phase 4
- Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenCompletedNCT02028364Phase 2
- Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast CancerStatus unknownNCT02025712Phase 2
- Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain TumorsStatus unknownNCT02015728Not applicable
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC StudyStatus unknownNCT02013089Not applicable
- A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed ChondrosarcomasSuspendedNCT02008019Phase 2
- Everolimus Post Orthotopic Liver TransplantStatus unknownNCT01998789Phase 2
- Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)WithdrawnNCT01997255Phase 2
- Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety StudyStatus unknownNCT01960829Phase 2
- A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisStatus unknownNCT01954693Phase 2
- Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast CancerTerminatedNCT01939418Phase 1/2
- Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant RecipientsStatus unknownNCT01927588Phase 4
- Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney CancerTerminatedNCT01888042Phase 2
- Exploring the Activity of RAD001 in Vestibular Schwannomas and MeningiomasCompletedNCT01880749Early Phase 1
- Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant DiseaseWithdrawnNCT01864070Phase 1
- Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerCompletedNCT01857193Phase 1
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell LymphomaCompletedNCT01854606Phase 1
- RAD001 in Advanced SarcomaCompletedNCT01830153Phase 2
- Myfortic in High MELD Liver TransplantationWithdrawnNCT01807767Not applicable
- Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone TherapyActive, not recruitingNCT01805271Phase 3
- Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable OsteosarcomaCompletedNCT01804374Phase 2
- The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the UrotheliumCompletedNCT01801137Phase 2
- Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal CancerTerminatedNCT01784978Phase 2
- Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS MetastasisCompletedNCT01783756Phase 1/2
- Pharmacokinetic of Everolimus and Atorvastatin Co-administrationCompletedNCT01780948Not applicable
- Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and ExemestaneTerminatedNCT01773460Phase 3
- Sequential Therapy in Metastatic Renal Cell CarinomaCompletedNCT01731158Phase 2
- Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexStatus unknownNCT01730209Phase 2/3
- Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With EverolimusCompletedNCT01715935Phase 2
- Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal CancerCompletedNCT01714765Phase 1
- The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver TransplantationCompletedNCT01707849Phase 3
- Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of TransplantationCompletedNCT01706471Phase 4
- Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung CancerCompletedNCT01700400Phase 1
- A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell CarcinomaTerminatedNCT01677390Phase 1
- Effects of the Use of "de Novo" Everolimus in Renal Tranplant PopulationStatus unknownNCT01663805Phase 4
- Certican (Everolimus) for Recipients of Kidney From HLA-identical Living DonorsCompletedNCT01653041Phase 4
- Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine TumorsTerminatedNCT01648465Phase 2
- Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney TransplantationCompletedNCT01640743Not applicable
- Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerCompletedNCT01637194Phase 1
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- Renal Transplantation in the Elderly - nEverOld StudyStatus unknownNCT01631058Phase 4
- 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT01626222Phase 3
- Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant RecipientsWithdrawnNCT01612299Not applicable
- Study of Everolimus in de Novo Renal Transplant RecipientsTerminatedNCT01609673Not applicable
- A Clinical Trial to Assess the Efficacy and Safety of the Conversion to EverolimusStatus unknownNCT01608412Phase 4
- Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerCompletedNCT01596140Phase 1
- Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)CompletedNCT01595984Phase 3
- A Prospective, Open Label Study of CERtican in KIdney TransplantationCompletedNCT01594268Phase 4
- Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETsCompletedNCT01590199Phase 1
- Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NETCompletedNCT01567488Phase 2
- The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's LymphomasCompletedNCT01567475Phase 1
- A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)CompletedNCT01566279Not applicable
- Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and ExerciseTerminatedNCT01561404Phase 4
- Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following ProstatectomyCompletedNCT01548807Phase 1
- Controlled Level EVERolimus in Acute Coronary SyndromesCompletedNCT01529554Phase 1/2
- Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced CholangiocarcinomaStatus unknownNCT01525719Phase 2
- Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALLCompletedNCT01523977Phase 1
- Gastric Cancer RAD001 StudyCompletedNCT01514110Phase 1/2
- Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell CarcinomaCompletedNCT01510119Phase 1/2
- PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation BloodCompletedNCT01509560Phase 2
- Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid TumorsTerminatedNCT01508104Phase 1
- Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal CancerCompletedNCT01490749Phase 1
- Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) PatientsCompletedNCT01490476Phase 2
- RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 ExpressionCompletedNCT01482299Phase 2
- Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsCompletedNCT01482156Phase 1
- A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesCompletedNCT01470209Phase 1
- Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft RecipientsCompletedNCT01469884Phase 4
- Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic MetastasesCompletedNCT01469572Phase 1
- Everolimus in Refractory Testicular Germ Cell CancerCompletedNCT01466231Phase 2
- Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell CancerCompletedNCT01462214Phase 1/2
- Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in AdultsStatus unknownNCT01455649Phase 4
- Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01453504Phase 1/2
- Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss PatientsCompletedNCT01430572Phase 1
- Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung CancerCompletedNCT01427946Phase 1/2
- Everolimus in de Novo Liver Transplantation: a Multicentre Randomized StudyStatus unknownNCT01423708Phase 2
- Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform NeurofibromasCompletedNCT01412892Phase 2
- A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's SarcomaTerminatedNCT01412515Phase 2
- Rotating Pazopanib and Everolimus to Avoid ResistanceCompletedNCT01408004Phase 2
- Efficacy of Certican® in Combination With Myfortic® in RenalStatus unknownNCT01399242Phase 4
- Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal CancerCompletedNCT01387880Phase 2
- Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium MycophenolateCompletedNCT01354301Phase 4
- BIBF 1120 and RAD001 in Solid Tumors - Phase ICompletedNCT01349296Phase 1
- Study of RAD001 for Treatment of NF2-related Vestibular SchwannomaTerminatedNCT01345136Phase 2
- Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven TumorsStatus unknownNCT01341834Phase 1
- Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell LymphomaCompletedNCT01334502Phase 1
- Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid TumorsCompletedNCT01334073Phase 1
- Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by SurgeryCompletedNCT01333085Phase 1/2
- Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation TherapyWithdrawnNCT01332279Phase 1
- Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine TumorCompletedNCT01324492Phase 1
- Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck CancerTerminatedNCT01313390Phase 1/2
- De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab InductionTerminatedNCT01312064Phase 4
- Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic CancerCompletedNCT01298713Phase 2